niagenbioscience.com (NAGE): רווח למניה בשנים עשר החודשים האחרונים

Expanding partnerships in the dietary supplement segment and Niagen deliveries for cell regeneration are creating strong momentum for Chromadex Corp (NAGE). The TTM net income per share snapshot visualizes this trend, with the metric currently at 0.12. Stable revenue is driven by B2B raw material sales to pharmaceutical companies, while the development of longevity technologies relies on collaboration with the world's leading scientific centers.

For Chromadex Corp (NAGE), this indicator serves as a measure of real business efficiency amid geopolitical restrictions on chemical procurement and the complexities of molecule certification. The metric is calculated as the ratio of net income to the total number of shares, reflecting the portion of earnings attributable to a single share. Analyzing the rolling annual earnings per share allows for an assessment of capital resilience against external logistical shocks.